CytoMed Therapeutics (NASDAQ: GDTC) chair ups exposure and funds LongevityBank R&D

Rhea-AI Filing Summary

CytoMed Therapeutics Limited reports that Chairman and Director Choo Chee Kong has offered to acquire up to 200,000 company shares from independent arm’s-length shareholders through private cash transactions, with a stated minimum acquisition of 100,000 shares. The company is not a party to these trades and receives no proceeds.

Separately, Mr. Choo, via his wholly owned entity EP Capital Inc., invested S$300,000 (approximately US$250,000) into subsidiary LongevityBank Pte Ltd. This increases EP Capital’s stake in LongevityBank from 6.4% to 12.0%, based on a S$5 million post-money valuation. LongevityBank plans to use the funds to establish a research and development laboratory to support product innovation and improve processes alongside the company’s existing cGMP manufacturing facility.

Insights

Corporate governance and capital allocation analyst

Insider increasing exposure and funding R&D at a small subsidiary.

Chairman Choo Chee Kong is pursuing private purchases of up to 200,000 shares from independent shareholders, with at least 100,000 shares planned. These are secondary transactions, so the company itself does not receive cash, but they do raise his personal exposure to the stock.

Through EP Capital Inc., he also committed S$300,000 (about US$250,000) to subsidiary LongevityBank, lifting EP Capital’s stake from 6.4% to 12.0% at a S$5 million post-money valuation. The funds are earmarked for an R&D lab supporting product innovation and cGMP-aligned process improvements, which ties capital directly to technical capabilities rather than general overhead.

Future disclosures in company filings may provide additional detail on the final number of shares acquired under the private purchase offer and the progress of LongevityBank’s R&D build-out.

Key Figures

Planned share purchase size: up to 200,000 shares Minimum planned acquisition: 100,000 shares EP Capital investment: S$300,000 (approx. US$250,000) +3 more

6 metrics

Planned share purchase size up to 200,000 shares Offered by Chairman via private share purchase agreements

Minimum planned acquisition 100,000 shares Chairman’s stated minimum share acquisition

EP Capital investment S$300,000 (approx. US$250,000) Cash invested into LongevityBank Pte Ltd

Post-money valuation S$5 million Valuation of LongevityBank after EP Capital investment

EP Capital stake before 6.4% Ownership in LongevityBank before new investment

EP Capital stake after 12.0% Ownership in LongevityBank after S$300,000 investment

Key Terms

private share purchase agreement, independent arm’s-length shareholders, post-money valuation, current Good Manufacturing Practice, +1 more

5 terms

private share purchase agreement financial

"offered to acquire up to 200,000 of the Company's shares via private share purchase agreement"

independent arm’s-length shareholders financial

"via private share purchase agreement with independent arm’s-length shareholders for cash consideration"

post-money valuation financial

"increased from 6.4% to 12.0%, based on a post-money valuation of S$5 million"

Post-money valuation is the total value of a company immediately after a new round of investment, equal to the company's value before the investment plus the new cash injected. It matters to investors because it sets the price for ownership shares, shows how much of the company each investor owns, and determines future dilution and return potential—like seeing a home's price tag after renovations to understand each owner's share.

current Good Manufacturing Practice technical

"existing current Good Manufacturing Practice (“cGMP”) facility"

Current good manufacturing practice (cGMP) are the up-to-date, enforced rules and standards that factories follow to make medicines, medical devices, and related products reliably safe and consistent. Think of it as a detailed recipe and factory checklist that covers cleanliness, equipment, staff training and record-keeping; meeting cGMP reduces the risk of recalls, regulatory shutdowns or lawsuits and thus protects product supply, company reputation and investor value.

cord blood-derived therapeutics medical

"engaged in licenced cord blood banking and the development of cord blood-derived therapeutics"

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/23/2026 - 12:14 PM Accepted by SEC EDGAR 06/23/2026 - 12:14 PM Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-41677

CytoMed Therapeutics Limited

(Exact name of registrant as specified in its charter)

1 Commonwealth Lane

#08-22

Singapore 149544

(Address of Principal Executive Office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F ☒ Form 40-F ☐

INFORMATION CONTAINED IN THIS FORM 6-K REPORT

On June 22, 2026, Mr. Choo Chee Kong, Chairman and Director of CytoMed Therapeutics Limited (the “Company”), has offered to acquire up to 200,000 of the Company's shares via private share purchase agreement with independent arm’s-length shareholders for cash consideration. Further announcement on the exact amount of shares acquired (minimum acquisition of 100,000 shares) will be made as soon as possible. The Company was not a party to these transactions and did not receive any proceeds therefrom. Mr Choo intends to continue engaging with more independent arm’s-length shareholders through privately negotiated transactions to further increase his shareholding in the Company.

In addition, Mr. Choo through his 100% ownership of EP Capital Inc., invested S$300,000 (approximately US$250,000) in LongevityBank Pte Ltd (“LongevityBank”), a subsidiary of the Company engaged in licenced cord blood banking and the development of cord blood-derived therapeutics. Following the investment, EP Capital Inc.’s shareholding in LongevityBank increased from 6.4% to 12.0%, based on a post-money valuation of S$5 million. The proceeds from this investment will be allocated towards the establishment of a research and development laboratory, enhancing our capabilities in product innovation and process improvement to complement the manufacturing processes of our existing current Good Manufacturing Practice (“cGMP”) facility.

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	CytoMed Therapeutics Limited
	By:	/s/ CHOO Chee Kong
	Name:	CHOO Chee Kong
Date: June 23, 2026	Title:	Director and Chairman

FAQ

What insider share purchase has CytoMed Therapeutics (GDTC) disclosed?

CytoMed Therapeutics disclosed that Chairman Choo Chee Kong has offered to acquire up to 200,000 company shares from independent arm’s-length shareholders through private cash transactions, with a minimum planned acquisition of 100,000 shares. The company is not a party to these trades and receives no proceeds.

Does CytoMed Therapeutics (GDTC) receive any cash from the chairman’s planned share purchases?

CytoMed Therapeutics does not receive any cash from the planned share purchases. The transactions are private deals between Chairman Choo Chee Kong and independent arm’s-length shareholders, so proceeds go to those selling shareholders, not to the company itself.

How much did EP Capital invest in CytoMed subsidiary LongevityBank Pte Ltd?

EP Capital Inc., wholly owned by Chairman Choo Chee Kong, invested S$300,000, approximately US$250,000, in LongevityBank Pte Ltd. This investment increases EP Capital’s ownership stake in LongevityBank and is based on a S$5 million post-money valuation for the subsidiary.

How did EP Capital’s ownership in LongevityBank change after the new investment?

Following the S$300,000 investment, EP Capital Inc.’s ownership in LongevityBank Pte Ltd increased from 6.4% to 12.0%. This higher stake reflects the additional capital contributed at a S$5 million post-money valuation, giving EP Capital a more significant position in the subsidiary.

How will LongevityBank use the S$300,000 investment from EP Capital?

LongevityBank plans to use the S$300,000 investment to establish a research and development laboratory. The lab is intended to enhance product innovation and process improvement, supporting and complementing manufacturing activities at CytoMed’s existing current Good Manufacturing Practice (cGMP) facility.

What business is LongevityBank Pte Ltd engaged in for CytoMed Therapeutics (GDTC)?

LongevityBank Pte Ltd is a subsidiary of CytoMed Therapeutics engaged in licensed cord blood banking and developing cord blood-derived therapeutics. It operates alongside CytoMed’s broader therapeutic activities and will use new funding to expand research and development capabilities.